SLC5A2 and type 2 diabetes mellitus: Recent clinical trials have demonstrated that medications targeting T2DM, including GLP-1 receptor agonists and SGLT2 inhibitors, lead to improved cardiovascular outcomes in populations both with, and without concomitant T2DM4,6.